Yesintek, formerly known as Bmab 1200, is a human interleukin-12 and -23 antagonist. The FDA has approved Yesintek (Ustekinumab-kfce), a biosimilar to Stelara (Ustekinumab), for the treatment of ...

Planegg-Martinsried, Germany / Amman, Jodan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into a licensing and supply agreement for the ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

Germany’s Formycon has entered into a licensing and supply agreement with MS Pharma for the commercialization of FYB202, ...

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

YESINKTEK is the sixth ustekinumab biosimilar approved by the FDA, behind Amgen’s WEZLANA (ustekinumab-auub), approved in Oct. 2023; Alvotech’s SELARSDI (ustekinumab-aekn), approved in April 2024; ...

The US Food and Drug Administration (FDA) has approved ustekinumab -kfce (Yesintek) as a biosimilar to ustekinumab (Stelara) for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, ...

Bangalore: Biocon has sold Eighty Lacs equity shares of Syngene International Limited for Rs. 686 crores. The transacted ...

Mean duration of Crohn's disease was 7.4 years. Nearly half (48.5%) had previous biologic therapy failure, 45.7% had previous ...

Biocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting ...

Prices for the first 10 drugs negotiated by Medicare fell from their initial net prices, but all drugs except one remained ...

Biocon Biologics Ltd announced today that the U.S. Food and Drug Administration has approved YESINTEK™ (Ustekinumab-kfce), a ...